Antiretroviral treatment in resource-poor settings: A view from India

Indian Journal of Medical Sciences

Volumn 61, Issue 7, 2007, Pages 390-397

  Vajpayee, Madhu ^a   Kaushik, Shweta ^a   Mojumdar, Kamalika ^a   Sreenivas, V ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus 1; India; Resource poor

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE AVAILABILITY; HEALTH ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PATIENT MONITORING; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 34447117677     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.33188     Document Type: Article

References (28)

1. Forum for Collaborative HIV Research. A meeting organized by the forum for collaborative HIV research: Transfer of HIV diagnostic and monitoring technologies into resource-poor settings. Washington, DC; 22 April 2002.
2. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001;358:404-9.
3. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients. response, survival and drug resistance. Lancet 2002;360:34-40.
4. Adje-Toure C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, et al. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS Drug Access Initiative in Abidjan, Cote d'Ivoire. AIDS 2003;17:S23-9.
5. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-95.
6. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004;36:967-71.
7. Jaffar S, Govender T, Garrib A, Welz T, Grosskurth H, Smith PG, et al. Antiretroviral treatment in resource-poor settings: Public health research priorities. Trop Med Int Health 2005;10:295-9.
8. Desvarieux M, Landman R, Liautaud B, Girard PM. Antiretroviral therapy in resource-poor countries: Illusions and Realities. Am J Pub Health 2005;95:1117-22.
9. National AIDS Control Organization (NACO). Surveillance for HIV infection/AIDS cases in India. Ministry of Health and Family Welfare, Government of India. 1986-1999. p. 220-6.
10. Vajpayee M, Kanswal S, Seth P, Wig N, Pandey RM. Tuberculosis infection in HIV-infected Indian patients. AIDS Patient Care STDs 2004;18:209-13.
11. th Conference on Retroviruses and Opportunistic Infections. Boston; February 22-25, 2005. Abstract 586.
12. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1-77.
13. 1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). Centers for Disease Control and Prevention. Morbid Mortal Wkly Rep 1997;46:1-29.
14. Mandy F, Nicholson J, McDougal J. Revised Guidelines for performing single-platform absolute CD4+ T-Cell determinations with CD45 gating for persons infected with HIV. Morbid Mortal Wkly Rep 2003;52:1-13.
15. Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH. Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res 2005;121:345-55.
16. Cecelia AJ, Balakrishnan P, Mohanakrishnan, Venkatakrishnan B, Solomon S, Kumarasamy N. Effective evaluation of novel low-cost CD4 monitoring assays. J Immunol Met 2006;316:158-62.
17. Rabkin M, El-Sadr Wafaa, Katzenstein DA, Mukherjee J, Masur H, Mugyenyi P, et al. Antiretroviral treatment in resource-poor settings: Clinical research priorities. Lancet 2002;360:1503-5.
18. Kent DM, McGrath D, Ioannidis PA, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: Setting the research agenda. Clin Infect Dis 2003;37:S13-24.
19. Garcia R, Badaro R, Netto EM, Silva M, Amorin FS, Ramos A, et al. Cross-sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients AIDS Res Hum Retroviruses 2006;22:1248-52.
20. Weiss L, French T, Waters M, Netherland J, Agins B, Finkelstein R. Adherence to HAART: Perspectives from clients in treatment support programs. Psychol Health Med 2006;11:155-70.
21. Gilks CF, Crowley S, Ekpini R, Grove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368:501-10.
22. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, et al. Human immuno-deficiency virus-1 RNA levels and CD4 lymphocyte counts during treatment for active tuberculosis, in South African patients. J Infect Dis 2003;187:1967-71.
23. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004;36:967-71.
24. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4 lymphocyte counts predict both response to anti retroviral therapy and therapeutic failure. Ann Intern Med 1997;126:939-45.
25. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active anti retroviral therapy. Ann Intern Med 2000;133:401-10.
26. Mezzaroma I, Carlesimo M, Pinter E, Alario C, Sacco G, Muratori DS, et al. Long-term evaluation of T-cell subsets and T- cell functions after HAART in advanced stage of HIV-1 Disease. AIDS 1999;13:1187-93.
27. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the 3 1/2 years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:168-75.
28. Lange CG, Lederman MM. Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J Antimicrob Chemother 2003;51:1-4.